Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

novartis europharm limited  - siponimod-aċidu fumariku - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosuppressanti selettivi - mayzent huwa indikat għall-kura ta ' pazjenti adulti bi sklerożi multipla progressiva sekondarja (spms), bil-marda attiva muri mill-irkadar jew l-immaġini tal-karatteristiċi ta'l-attività infjammatorja.

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

3m health care limited - rivastigmine - marda ta 'alzheimer - psychoanaleptics, , anticholinesterases - trattament sintomatiku ta 'dimenzja ta' alzheimer ħafifa għal moderatament gravi.

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - lewkimja, mjeloġenika, kronika, bcr-abl pożittiva - aġenti antineoplastiċi - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaċċini - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

mylan pharmaceuticals limited - pregabalin - anxiety disorders; epilepsy - anti-epilettiċi, - newropatiku painpregabalin mylan huwa indikat għat-trattament tal-uġigħ nevrotiku periferali u ċentrali f'persuni adulti. epilepsypregabalin mylan huwa indikat bħala terapija aġġuntiva f'persuni adulti b'aċċessjonijiet parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja. ta'ansjetà ġeneralizzata disorderpregabalin mylan huwa indikat għall-kura ta 'disturb ta' ansjetà Ġeneralizzata (gad-generalised anxiety disorder) f'persuni adulti.

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - iebes capsuleszerit huwa indikat flimkien ma ' prodotti mediċinali antiretrovirali oħra għat-trattament ta infettati bl-hiv pazjenti adulti u pazjenti pedjatriċi ('l fuq minn l-età ta'tliet xhur) biss meta l-mediċini antiretrovirali oħra ma jistgħux jintużaw. it-tul tat-terapija b'zerit għandha tiġi limitata għall-iqsar żmien possibbli. trab għall-ħalq solutionzerit huwa indikat flimkien ma ' prodotti mediċinali antiretrovirali oħra għat-trattament ta infettati bl-hiv pazjenti adulti u pazjenti pedjatriċi (mit-twelid) biss meta l-mediċini antiretrovirali oħra ma jistgħux jintużaw. it-tul tat-terapija b'zerit għandha tiġi limitata għall-iqsar żmien possibbli.

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

n.v. organon - corifollitropin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing limited - meloxicam - oxicams, anti-inflammatory and anti-rheumatic products, non-steroids - dogs; horses; cats; cattle; pigs - dogsalleviation mill-infjammazzjoni u uġigħ akut kif ukoll kroniku muskolu-skeltrali disturbi fil-klieb. biex tnaqqas l-uġigħ u l-infjammazzjoni wara operazzjoni wara kirurġija ortopedika u tessut artab. catsreduction tal-uġigħ postoperatorju wara ovariohysterectomy u minuri tat-tessut artab. għas-serħan mill-indeboliment ħafif għal moderat tal-uġigħ postoperatorju u l-infjammazzjoni wara interventi kirurġiċi fil-qtates, e. ortopedika u tat-tessut artab. għas-serħan mill-uġigħ u l-infjammazzjoni akuta u kronika disturbi muskolu-skeletrali fil-qtates. cattlefor-użu fil-infezzjoni respiratorja akuta b'terapija antibijotika xierqa biex jitnaqqsu s-sinjali kliniċi. għal użu fid-dijarea flimkien ma 'terapija mill-ġdid ta' idratazzjoni mill-ħalq biex jitnaqqsu s-sinjali kliniċi f'għoġġiela ta 'aktar minn ġimgħa ta' età u baqar żgħar li ma jreddgħux. għal terapija aġġuntiva fit-trattament ta 'mastite akuta, flimkien ma' terapija antibijotika. pigsfor-użu fil-disturbi lokomotorji mhux infettivi biex jitnaqqsu s-sintomi ta'zappip u ta'infjammazzjoni. għal terapija aġġuntiva fit-trattament ta 'settiċemija puerperali u toxaemia (sindrome mastite-metritis-agalactia) b'terapija antibijotika xierqa. għall-eżenzjoni ta 'uġigħ wara l-operazzjoni assoċjat ma' tessut artab minuri bħal kastrazzjoni. horsesalleviation tal-infjammazzjoni u serħan mill-uġigħ akut kif ukoll kroniku muskolu-skeltrali disturbi fil-żwiemel. għall-eżenzjoni ta 'uġigħ assoċjat ma' kolika ekwina.

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - anagrelide - tromboċitemja, essenzjali - aġenti antineoplastiċi - xagrid huwa indikat għat-tnaqqis tal-għadd tal-platelets elevati fil-pazjenti at-risk essenzjali-thrombocythaemia (et) li huma intolerant biex-terapija kurrenti tagħhom jew l-għadd tagħhom platelets elevati ma jiġux imnaqqsa għal livell aċċettabbli mill-terapija kurrenti tagħhom. l-riskju patientan fil-riskju et huwa ddefenit b'waħda jew aktar mill-karatteristiċi li ġejjin:>60 sena ta ' età jew l;għadd tal-plejtlets >1000 x 109/l jew;l-istorja tal-każijiet tromboemorragiċi.

Avrupa Birliği - Maltaca - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - aġenti li jimmodifikaw il-lipidi - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.